DenCe-ctive – Use of autologous Thrombocytes for induction of Dendritic Cell activity
The therapeutic use of dendritic cells in vaccination
therapy requires prior activation of these immune cells. The invention exploits the ability of stimulated thrombocytes to activate dendritic cells ex vivo thereby offering the unique possibility of autologous activation. Immune therapy using activated dendritic cells is a well established approach used for various therapies including cancer vaccination strategies. An enormous market potential is expected. The invention provides the first method triggering an autologous maturation of dendritic cells into potent antigen presenting cells. Thus, the method constitutes a highly efficacious approach for inducing T-cell responses. The simple and efficient activation strategy is strikingly easy to handle and compatible with established immunotherapy protocols.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…
